Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia



Status:Recruiting
Conditions:Cancer, Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:June 2006

Use our guide to learn which trials are right for you!

Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial


RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming,
growing, or coming back. The use of Bowman-Birk inhibitor concentrate, a substance made from
soy, may keep cancer from forming in patients with oral leukoplakia.

PURPOSE: This randomized phase II trial is studying how well Bowman-Birk inhibitor
concentrate works in preventing cancer in patients with oral leukoplakia.


OBJECTIVES:

Primary

- Determine if chemoprevention by the Bowman-Birk inhibitor concentrate (BBIC) can
prevent cancer in patients with oral leukoplakia (OL).

- Determine the clinical and histologic response rate of OL to BBIC.

Secondary

- Measure the effect of BBIC on intermediate marker endpoint levels.

- Correlate the clinical and histologic responses of OL with cellular levels of
proteolytic activity, erb-B2 (neu), retinioc acid receptor β, bcl-2, and mutant p53
expression, and serum levels of neu.

- Determine the individual and group side effects of BBIC.

OUTLINE: This is a multicenter, randomized, double-blind, placebo-controlled, study.

Prior to randomization, all patients receive oral placebo for 4 weeks. Patients who show
good compliance (> 75% packet count) are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive oral placebo twice daily for 6 months in the absence of
disease progression or unacceptable toxicity.

Patients complete questionnaires about diet, tobacco, and alcohol usage at baseline and at
the completion of study treatment.

Blood, urine, and biopsy tissue are collected at baseline and at the completion of study
treatment. Oral mucosal cells are collected at baseline, during the run-in phase, at
randomization, after completion of study treatment, and at 3 months after completion of
study treatment. Samples are examined for protease activity, levels of bcl-2 and erbB-2,
mutant p53 oncogene expression and epidermal growth factor receptor, and retinoic acid
receptor-β expression.

After completion of study treatment, patients are followed at 3 months.

PROJECTED ACCRUAL: A total of 210 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

- Histologically and clinically confirmed oral leukoplakia and/or erythroplakia

- Bidimensionally measurable disease (≥ 100 mm^2 for total area of all lesions) after
biopsy

- No presence of obvious head and neck aerodigestive tract cancer, carcinoma in situ,
or previously treated head and neck cancer within the past 2 years

PATIENT CHARACTERISTICS:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of allergic reaction to soybeans, sorbitol, sucrose, artificial
flavorings, aspartame, saccharin, or lidocaine

PRIOR CONCURRENT THERAPY:

- At least 6 months since prior Bowman-Birk inhibitor concentrate

- At least 6 months since prior participation in another randomized clinical trail

- At least 3 months since prior systemic steroids or topical oral steroid preparations

- Topical nasal steroid sprays or cutaneous preparations with minimal systemic
absorption for nasal or dermatologic disorders allowed

- More than 6 months since prior beta carotene capsules

- At least 2 years since prior retinoid or other beta carotene therapy, including >
25,000 IU of vitamin A for any reason

- Up to 2 multivitamins per day allowed
We found this trial at
5
sites
1400 Northwest 12th Avenue
Miami, Florida 33136
(305) 243-1000
University of Miami Sylvester Comprehensive Cancer Center - Miami Sylvester Comprehensive Cancer Center integrates all...
?
mi
from
Miami, FL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
(617) 632-3000
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Founded in 1997, Dana-Farber/Harvard Cancer Center (DF/HCC) was...
?
mi
from
Boston, MA
Click here to add this to my saved trials
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
(310) 825-5268
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials